Repeat Ischemic Colitis in a Patient Taking Quetiapine

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

To the Editor: Aripiprazole long-acting injectable (LAI) is a lyophilized powder form of the second-generation antipsychotic aripiprazole and was approved for use by the US Food and Drug Administration in 2013. LAIs are felt to offer the patient convenience with less frequent dosing and, therefore, improve compliance. Studies have shown that LAIs demonstrate improved prevention of next hospital stay and reduce treatment failure compared to oral antipsychotics.